155 related articles for article (PubMed ID: 11137485)
1. Disclosure of familial genetic information: perceptions of the duty to inform.
Lehmann LS; Weeks JC; Klar N; Biener L; Garber JE
Am J Med; 2000 Dec; 109(9):705-11. PubMed ID: 11137485
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.
Lehmann LS; Weeks JC; Klar N; Garber JE
Genet Med; 2002; 4(5):346-52. PubMed ID: 12394347
[TBL] [Abstract][Full Text] [Related]
3. Medicolegal and ethical issues in genetic cancer syndromes.
Anderlik MR; Lisko EA
Semin Surg Oncol; 2000 Jun; 18(4):339-46. PubMed ID: 10805956
[TBL] [Abstract][Full Text] [Related]
4. The Double Helix: Applying an Ethic of Care to the Duty to Warn Genetic Relatives of Genetic Information.
Weaver M
Bioethics; 2016 Mar; 30(3):181-7. PubMed ID: 26194147
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
6. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.
Matloff ET; Shappell H; Brierley K; Bernhardt BA; McKinnon W; Peshkin BN
J Clin Oncol; 2000 Jun; 18(12):2484-92. PubMed ID: 10856109
[TBL] [Abstract][Full Text] [Related]
7. Professional challenges in cancer genetic testing: who is the patient?
Chan-Smutko G; Patel D; Shannon KM; Ryan PD
Oncologist; 2008 Mar; 13(3):232-8. PubMed ID: 18378533
[TBL] [Abstract][Full Text] [Related]
8. Legal and ethical issues in genetic testing and counseling for susceptibility to breast, ovarian and colon cancer.
Dickens BM; Pei N; Taylor KM
CMAJ; 1996 Mar; 154(6):813-8. PubMed ID: 8634959
[TBL] [Abstract][Full Text] [Related]
9. A descriptive study of BRCA1 testing and reactions to disclosure of test results.
Lynch HT; Lemon SJ; Durham C; Tinley ST; Connolly C; Lynch JF; Surdam J; Orinion E; Slominski-Caster S; Watson P; Lerman C; Tonin P; Lenoir G; Serova O; Narod S
Cancer; 1997 Jun; 79(11):2219-28. PubMed ID: 9179070
[TBL] [Abstract][Full Text] [Related]
10. Genetic testing: do healthcare professionals have a duty to tell a patient's family members that they may be at risk?
Marta MR
J Healthc Risk Manag; 1999; 19(3):26-38. PubMed ID: 10538434
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
12. Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.
Chopra I; Kelly KM
J Health Commun; 2017 Feb; 22(2):143-152. PubMed ID: 28112991
[TBL] [Abstract][Full Text] [Related]
13. Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.
Shkedi-Rafid S; Ofer-Bialer G; Meiner V; Calderon-Margalit R
Public Health Genomics; 2013; 16(4):174-83. PubMed ID: 23816973
[TBL] [Abstract][Full Text] [Related]
14. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
15. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
17. Comparing the attitudes of physicians and non-physicians toward communicating a patient's BRCA1 mutation to a first-degree relative against a patient's wishes.
Zebrack JE; Yang W; Milone M; Coppes MJ
J Community Genet; 2022 Aug; 13(4):403-410. PubMed ID: 35596048
[TBL] [Abstract][Full Text] [Related]
18. The "duty to warn" a patient's family members about hereditary disease risks.
Offit K; Groeger E; Turner S; Wadsworth EA; Weiser MA
JAMA; 2004 Sep; 292(12):1469-73. PubMed ID: 15383518
[TBL] [Abstract][Full Text] [Related]
19. Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing.
Goelen G; Rigo A; Bonduelle M; De Grève J
J Clin Oncol; 1999 May; 17(5):1595-600. PubMed ID: 10334549
[TBL] [Abstract][Full Text] [Related]
20. Public health aspects of breast cancer gene testing in Canada. Part 1: risks and interventions.
Elwood JM
Chronic Dis Can; 1999; 20(1):3-13. PubMed ID: 10352130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
